Document is current
Any future updates will be listed below
-
Authors
Okamura, Kazumi http://orcid.org/0000-0002-4103-7366
Nagayama, Satoshi
Tate, Tomohiro
Chan, Hiu Ting
Kiyotani, Kazuma
Nakamura, Yusuke
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K16458)
- License Information
-
More Information
Article History
Received: 20 February 2022
Accepted: 16 May 2022
First Online: 23 May 2022
Declarations
:
: The study protocol was approved by the Institutional Review Board of Cancer Institute Hospital of Japanese Foundation for Cancer Research (2018–1021). Our study’s involvement with human subjects complies with the Declaration of Helsinki.
: All patients signed informed consent regarding publishing their data.
: Kazuma Kiyotani reported advisory roles to Cancer Precision Medicine Inc, Japan. Yusuke Nakamura is a stockholder and an advisor of OncoTherapy Science, Inc, Japan.
